Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

@article{Kantoff2010SipuleucelTIF,
  title={Sipuleucel-T immunotherapy for castration-resistant prostate cancer.},
  author={Philip W. Kantoff and Celestia S. Higano and Neal D Shore and E. R. Berger and Eric Small and David F Penson and Charles H. Redfern and Anna C. Ferrari and Robert Dreicer and Robert Brownell Sims and Yi Xu and Mark Walter Frohlich and Paul Schellhammer},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 5},
  pages={
          411-22
        }
}
  • Philip W. Kantoff, Celestia S. Higano, +10 authors Paul Schellhammer
  • Published 2010
  • Medicine
  • The New England journal of medicine
  • BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. METHODS In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer  
    ConditionsProstate Adenocarcinoma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    This is a nonrandomized, open-label trial of avelumab in subjects with metastatic castration-resistant prostate cancer (mCRPC) experiencing PSA or radiographic progression while… Expand
    ConditionsMetastatic Castration-resistant Prostate Cancer
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or… Expand
    ConditionsProstate Cancer
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in… Expand
    ConditionsMetastatic Castration-resistant Prostate Cancer
    InterventionDevice, Drug, Radiation

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 3,940 CITATIONS, ESTIMATED 49% COVERAGE

    Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

    • 2012
    VIEW 4 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis

    VIEW 15 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

    VIEW 5 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.

    VIEW 7 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists

    VIEW 3 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Sipuleucel-T and immunotherapy in the treatment of prostate cancer

    VIEW 11 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2008
    2020

    CITATION STATISTICS

    • 155 Highly Influenced Citations

    • Averaged 247 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 133 REFERENCES

    Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.